In the last trading session, 5.94 million shares of the Monte Rosa Therapeutics Inc (NASDAQ:GLUE) were traded, and its beta was 1.43. Most recently the company’s share price was $5.00, and it changed around -$0.07 or -1.38% from the last close, which brings the market valuation of the company to $306.85M. GLUE currently trades at a discount to its 52-week high of $8.84, offering almost -76.8% off that amount. The share price’s 52-week low was $2.44, which indicates that the current value has risen by an impressive 51.2% since then. We note from Monte Rosa Therapeutics Inc’s average daily trading volume that its 10-day average is 0.79 million shares, with the 3-month average coming to 269.57K.
Monte Rosa Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 8 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 0 recommended GLUE as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight. Monte Rosa Therapeutics Inc is expected to report earnings per share of -0.49 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Monte Rosa Therapeutics Inc (NASDAQ:GLUE) trade information
Instantly GLUE has showed a red trend with a performance of -1.38% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 5.55 on recent trading dayincreased the stock’s daily price by 9.91%. The company’s shares are currently down -11.50% year-to-date, but still down -5.66% over the last five days. On the other hand, Monte Rosa Therapeutics Inc (NASDAQ:GLUE) is -15.68% down in the 30-day period. We can see from the shorts that 3.27 million shares have been sold at a short interest cover period of 13.71 day(s).
Monte Rosa Therapeutics Inc (GLUE) estimates and forecasts
Monte Rosa Therapeutics Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -36.39 percent over the past six months and at a 28.14% annual growth rate that is well above the industry average of 17.60%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 30.00% in revenue this quarter, and will report an increase of 15.50% in the next quarter.
Consensus estimates provided by 7 financial analysts predict the company will bring in an average of 2.62M in revenue for the current quarter. 7 analysts expect Monte Rosa Therapeutics Inc to make 3.05M in revenue for the current ending quarter.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -96.71%.
GLUE Dividends
Monte Rosa Therapeutics Inc’s next quarterly earnings report is expected to be released in November.
Monte Rosa Therapeutics Inc (NASDAQ:GLUE)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.71% of Monte Rosa Therapeutics Inc shares, and 86.85% of them are in the hands of institutional investors. The stock currently has a share float of 87.47%. Monte Rosa Therapeutics Inc stock is held by 116.0 institutions, with NEA MANAGEMENT COMPANY, LLC being the largest institutional investor. By 2024-06-30, it held 12.7872% of the shares, which is about 7.69 million shares worth $28.77 million.
PRICE T ROWE ASSOCIATES INC /MD/, with 9.9368% or 5.98 million shares worth $22.36 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
